Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein–Barr virus (EBV)–related neoplasm with male dominance and a poor prognosis. A better understanding of the genetic alterations and their functional roles in ENKTCL could help improve patient stratification and treatments. In this study, we performed a comprehensive genetic analysis of 178 ENKTCL cases to delineate the landscape of mutations, copy number alterations (CNA), and structural variations, identifying 34 driver genes including six previously unappreciated ones, namely, HLA-B, HLA-C, ROBO1, CD58, POT1, and MAP2K1. Among them, CD274 (24%) was the most frequently altered, followed by TP53 (20%), CDKN2A (19%), ARID1A (15%), HLA-A (15%), BCOR (14%), and MSN (14%). Chromosome X losses were the most common arm-level CNAs in females (∼40%), and alterations of four X-linked driver genes (MSN, BCOR, DDX3X, and KDM6A) were more frequent in males and females harboring chromosome X losses. Among X-linked drivers, MSN was the most recurrently altered, and its expression was lost in approximately one-third of cases using immunohistochemical analysis. Functional studies of human cell lines showed that MSN disruption promoted cell proliferation and NF-κB activation. Moreover, MSN inactivation increased sensitivity to NF-κB inhibition in vitro and in vivo. In addition, recurrent deletions were observed at the origin of replication in the EBV genome (6%). Finally, by integrating the 34 drivers and 19 significant arm-level CNAs, nonnegative matrix factorization and consensus clustering identified two molecular groups with different genetic features and prognoses irrespective of clinical prognostic factors. Together, these findings could help improve diagnostic and therapeutic strategies in ENKTCL.
Significance: Integrative genetic analyses and functional studies in extranodal NK/T-cell lymphoma identify frequent disruptions of X-linked drivers, reveal prognostic molecular subgroups, and uncover recurrent MSN alterations that confer sensitivity to NF-κB inhibition.
CITE THIS COLLECTION
FUNDING
Japan Agency for Medical Research and Development (AMED)
Japan Society for the Promotion of Science (JSPS) KAKENHI
SGH Foundation (SGH財団)
Princess Takamatsu Cancer Research Fund
MSD Life Science Foundation
Takeda Science Foundation (TSF)
the Foundation ARC pour la recherche sur le cancer
the France Lymphome Espoir association
the GEFLUC Paris-Ile de France
Institut Carnot CALYM
JANSSEN Horizon
Bristol-Myers Squibb Foundation
Agence Nationale de la Recherche under the Investissements d’avenir program
ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Sante/National Alliance for Life Sciences and Health)
European Hematology Association (EHA)
Programme exploration Japon Sciences de la vie
French Institute of Health and Medical Research (poste d’accueil INSERM)
Japanese Society of Hematology (JSH)
Imagine Institute
SHARE
Usage metrics
Read the peer-reviewed publication

AUTHORS (65)
- YIYuta ItoAMAmira MaroufYKYasunori KogureJKJunji KoyaRLRaphaël LiévinJBJulie BruneauMTMariko TabataYSYuki SaitoSSSumito ShingakiMYMitsuhiro YuasaKYKentaro YamaguchiKMKoichi MurakamiRWRobert WeilMVManon VavasseurGAGuillaume P. AndrieuMLMehdi LatiriLVLayla VeleanuMDMichaël DussiotIAIsabelle AndréAJAkshay Joshi